Explore
Companies
Investors
Top 50
Streams
Trending tech news
Latest investments
Latest acquisitions
Products
Automate
Trackers
Innovation Services
About Index
Index
By TNW
Log in
Register
Jounce Therapeutics
3163
Jounce Therapeutics
Technology
Biotechnology
Jounce Therapeutics is developing cancer immune-therapies to harness the immunesystem to attack cancerous cells and tumors.
Suggest edits
Founded
2013
Raised
$158M
Follow us
Also headquartered in Cambridge
MIT
Raspberry Pi
ARM
Xconomy
Biogen
Money Mover
HubSpot
Formlabs
Akamai
General Catalyst
Companies in the same industry
CrossRoads Extremity Systems
Longevity Biotech
Binhui Biotech
United Health - Beijing Zhongliankang Biological Technology
3D Medicines
Twentyeight-Seven Therapeutics
FirstString Research
Carbiotix
Mebias Discovery
Dyno Therapeutics
Alexa global traffic share
Overview
Funding
2
Add info
Latest funding
$102,000,000
IPO - 2017
$56,000,000
Venture capital (Series B) - 2015
Redmile Group
Foresite Capital
Wellington Management
+5
Team Size
50+
Employees
I work here
Location
Cambridge
,
United States
Headquarters
Explore Cambridge
$102,000,000
IPO
Xconomy
Jounce Gets $102M As Biotech IPOs Gain Steam in ’17
Stock markets
Earnings
$56,000,000
Venture capital (Series B)
VentureWire
The Daily Startup: Jounce Therapeutics Raises $56M as Immunotherapy Stays Hot
Funding
